Drug intelligence / Profile preview

TFB-00640

Development stage: Preclinical
Lead developer: ThirtyFiveBio
Modality: Small Molecules
Administration: Oral

Overview

TFB-00640 is a potent, selective, orally administered small molecule antagonist of G protein-coupled receptor 35 (GPR35) being developed by ThirtyFiveBio for the treatment of ulcerative colitis. GPR35 is a genetically validated target in inflammatory bowel disease, and its activation is associated with epithelial dysfunction and damage in colitis. By inhibiting GPR35, TFB-00640 is designed to prevent harmful signaling in the gut lining, thereby protecting the gut epithelium from inflammatory damage and creating a protective 'gut epithelial shield.' The drug is currently in preclinical development, with investigational new drug (IND)-enabling studies underway to support the initiation of clinical trials.

Targets

GPR35 (G-protein Coupled Receptor 35)

Beyond the preview

Go deeper on TFB-00640.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TFB-00640.

Explore the full profile